CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall
Overview
US biotechnology firm reported Q3 net loss narrowed yr/yr as R&D expenses declined
Company's general and administrative expenses rose on higher consulting and personnel costs
Company aims to complete first pipeline-building transaction by year-end 2026
Outlook
CNS Pharmaceuticals aims to complete its first pipeline-building transaction by year-end 2026
Company is in advanced discussions to acquire or license new therapeutic assets
Future R&D expenses will depend on timing and nature of any acquired assets
Result Drivers
LOWER CLINICAL COSTS - R&D expenses fell due to lower clinical costs for Berubicin after completion of enrollment and patient treatments, and reduced TPI 287 manufacturing costs
HIGHER BUSINESS DEVELOPMENT COSTS - General and administrative expenses rose mainly due to higher consulting expenses related to business development and increased personnel-related costs
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.24 | ||
Q3 Net Loss | $2.5 mln |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CNS Pharmaceuticals Inc is $10.00, about 246% above its November 13 closing price of $2.89
Reuters Recommended Reads
Nov 16 - Prelude Therapeutics Q3 net loss narrows as expenses fall
Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs
Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)